TrialPath
Crohn's disease · Atlanta

Crohn's disease clinical trials in Atlanta

20 recruiting crohn disease studies within range of Atlanta. Click any trial for full eligibility criteria and contact info.

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722 · Crohn Disease
Recruiting

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

PhasePhase 2 / Phase 3
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 394 more
SponsorJanssen Research & Development, LLC
▾Tap for details
Apply

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320 · Crohn's Disease (CD)
Recruiting

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.

PhasePhase 3
TypeInterventional
Age2 Years – 17 Years
WherePhoenix, Arizona, United States + 95 more
SponsorTakeda
▾Tap for details
Apply

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232 · Crohn Disease
Recruiting

The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

PhasePhase 3
TypeInterventional
Age18 Years
WhereDothan, Alabama, United States + 163 more
SponsorJanssen Research & Development, LLC
▾Tap for details
Apply

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345 · Autoimmune Disease, Crohn Disease, Dermatomyositis
Recruiting

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.

PhasePhase 1
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 51 more
SponsorNational Cancer Institute (NCI)
▾Tap for details

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332 · Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Recruiting

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

PhasePhase 3
TypeInterventional
Age3 Years
WhereAtlanta, Georgia, United States + 52 more
SponsorJanssen Research & Development, LLC
▾Tap for details
Apply

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Recruiting

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 65 more
SponsorMirador Therapeutics, Inc.
▾Tap for details
Apply

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073 · Crohn's Disease
Recruiting

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

PhasePhase 3
TypeInterventional
Age2 Years – 17 Years
WhereLos Angeles, California, United States + 84 more
SponsorJanssen Research & Development, LLC
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801 · Crohn's Disease
Recruiting

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

PhasePhase 3
TypeInterventional
Age16 Years – 80 Years
WhereDothan, Alabama, United States + 498 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461 · Crohn's Disease
Recruiting

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereMurrieta, California, United States + 200 more
SponsorTakeda
▾Tap for details
Apply

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073 · Colitis, Ulcerative, Crohn Disease
Recruiting

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereScottsdale, Arizona, United States + 70 more
SponsorEli Lilly and Company
▾Tap for details
Apply

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878 · Moderately to Severely Active Crohns Disease
Recruiting

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

PhasePhase 3
TypeInterventional
Age16 Years – 80 Years
WhereDothan, Alabama, United States + 374 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Recruiting

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.

PhasePhase 4
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 100 more
SponsorTakeda
▾Tap for details
Apply

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843 · Crohn Disease
Recruiting

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).

PhasePhase 3
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 286 more
SponsorJanssen Research & Development, LLC
▾Tap for details
Apply

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Recruiting

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.

PhasePhase 3
TypeInterventional
Age2 Years – 19 Years
WhereSan Francisco, California, United States + 68 more
SponsorEli Lilly and Company
▾Tap for details
Apply

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099 · Crohn Disease
Recruiting

The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereScottsdale, Arizona, United States + 70 more
SponsorEli Lilly and Company
▾Tap for details
Apply

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891 · Moderately to Severely Active Crohns Disease
Recruiting

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

PhasePhase 3
TypeInterventional
Age16 Years – 80 Years
WhereDothan, Alabama, United States + 207 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Recruiting

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

PhasePhase 2
TypeInterventional
Age18 Years – 85 Years
WhereLancaster, California, United States + 223 more
SponsorMorphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
▾Tap for details
Apply

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777 · Crohn's Disease
Recruiting

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.

PhasePhase 3
TypeInterventional
Age2 Years – 17 Years
WhereLos Angeles, California, United States + 80 more
SponsorEli Lilly and Company
▾Tap for details
Apply

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931 · Crohn's Disease
Recruiting

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 weeks with: * Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance Study (EFC18327). The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled study visits for participants who continue to the Pivotal Maintenance Study (EFC18327) will be up to 8 (Sub-Study 1 and Sub-Study 2) and up to 15 for participants who enroll in Sub-Study 3.

PhasePhase 3
TypeInterventional
Age16 Years – 80 Years
WherePeoria, Arizona, United States + 460 more
SponsorSanofi
▾Tap for details
Apply

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting

The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

PhasePhase 3
TypeInterventional
Age2 Years
WhereMobile, Alabama, United States + 97 more
SponsorTakeda
▾Tap for details
Apply